Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus PERCODAN DEMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AND DEMEROL versus PERCODAN DEMI.
ATROPINE AND DEMEROL vs PERCODAN-DEMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
None Documented
None Documented
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination